1. Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients
- Author
-
Liang,Shuang, Liang,Yan-Jun, Li,Zhao, Wang,Yong, Guo,Xin-Ru, Zhang,Chao-yang, Zhang,Chun, Wu,Jie, Wang,Xiao-Long, Li,Yi-Sha, Cai,Guang-Yan, Chen,Xiang-Mei, Liang,Shuang, Liang,Yan-Jun, Li,Zhao, Wang,Yong, Guo,Xin-Ru, Zhang,Chao-yang, Zhang,Chun, Wu,Jie, Wang,Xiao-Long, Li,Yi-Sha, Cai,Guang-Yan, and Chen,Xiang-Mei
- Abstract
Shuang Liang,1 Yan-Jun Liang,1 Zhao Li,2 Yong Wang,1 Xin-Ru Guo,1 Chao-yang Zhang,1 Chun Zhang,1 Jie Wu,1 Xiao-Long Wang,1 Yi-Sha Li,1 Guang-Yan Cai,1 Xiang-Mei Chen1 1Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese Peopleâs Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, Peopleâs Republic of China; 2Haikou Peopleâs Hospital Affiliated to Xiangya School of Medicine, Haikou, Peopleâs Republic of ChinaCorrespondence: Guang-Yan Cai, Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese Peopleâs Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, Peopleâs Republic of China, Tel +86 13601062936, Fax +86 010-68130297, Email caiguangyan@sina.comPurpose: Tacrolimus is recommended by KDIGO Clinical Practice Guidelines as an initial therapy for the treatment of membranous nephropathy (MN). However, little is known about the factors that influence response and recurrence of the disease after tacrolimus therapy, and there are limited data regarding the duration of tacrolimus treatment. Here, we present a real-world retrospective cohort study of 182 MN patients treated with tacrolimus, aiming to assess the efficacy and safety of tacrolimus in the treatment of MN.Patients and Methods: The clinical data of 182 patients with MN treated with tacrolimus and followed up for at least one year were analyzed retrospectively for the efficacy and safety of tacrolimus.Results: The mean follow-up period was 27.3 (19.3â 41.6) months. A total of 154 patients (84.6%) achieved complete or partial remission, and 28 patients (15.4%) did not. Multivariate Cox regression analysis showed that male and higher baseline
- Published
- 2023